Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 09/30 10:01:05 pm
62.41 USD   +0.81%
09/29 MERCK : Congratulates Guatemala as Fourth Country in Latin America t..
09/29 MERCK FOUNDATIO : Grant Expands YMCA’s Diabetes Prevention Pro..
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Dire..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CEST
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
09/29 MERCK : New Herpes Zoster Study Findings Have Been Reported from Merck & Company..
09/29 MERCK : Congratulates Guatemala as Fourth Country in Latin America to Achieve WH..
09/29 MERCK : Researchers from Merck & Company Report Recent Findings in Molecular Pha..
09/29 MERCK FOUNDATION : Grant Expands YMCA’s Diabetes Prevention Program in Fiv..
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
09/28 MSD ANIMAL HEALTH : Demonstrates Commitment to Eliminate Rabies Worldwide with D..
09/28 MERCK : Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy..
09/23DJMERCK : Keytruda Finds Fast Entry Into China Via Medical-Tourism Push
09/23 MERCK : to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October..
09/21 MERCK : Geneva Advisors Lowers stake in Merck & Co. (MRK)
More news
Sector news : Pharmaceuticals - NEC
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30DJSHIRE : Files 8K - Other Events
09/30DJNovo Nordisk Announces Job Cuts
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/29 Novel Checkpoints Add To The Parp Showdown
09/29 Shire Cedes Biosimilar Field
09/29 Yellen And Clinton Combo To Take Market Higher
09/28 Enrollment underway in Bayer and Merck's large-scale study of vericiguat in h..
09/27 Real Estate Leader CXW Gains Upside As Price Sags
Advertisement
Financials ($)
Sales 2016 39 716 M
EBIT 2016 13 608 M
Net income 2016 5 662 M
Debt 2016 5 481 M
Yield 2016 2,94%
P/E ratio 2016 30,05
P/E ratio 2017 20,36
EV / Sales 2016 4,45x
EV / Sales 2017 4,38x
Capitalization 171 194 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,1 $
Spread / Average Target 6,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.17.21%171 194
JOHNSON & JOHNSON14.16%320 836
ROCHE HOLDING LTD.-11.51%216 029
NOVARTIS AG-10.14%209 049
PFIZER INC.3.22%202 108
GLAXOSMITHKLINE PLC19.99%104 124
More Results